Consolidated Statements of Operations (Unaudited) - USD ($) |
3 Months Ended | 12 Months Ended | ||
|---|---|---|---|---|
Nov. 30, 2019 |
Nov. 30, 2018 |
Aug. 31, 2019 |
Aug. 31, 2018 |
|
| OPERATING EXPENSES | ||||
| General and administrative | $ 403,159 | $ 205,501 | $ 952,334 | $ 508,278 |
| Professional fees | 266,227 | 167,293 | 1,164,695 | 585,069 |
| Research and development | 666,938 | 184,039 | 1,091,992 | 1,249,854 |
| Depreciation | 124 | 70 | 510 | 290 |
| Total Operating Expenses | 1,336,448 | 556,903 | 3,209,531 | 2,343,491 |
| Loss from Operations | (1,336,448) | (556,903) | (3,209,531) | (2,343,491) |
| OTHER INCOME (EXPENSE) | ||||
| Other income | 586 | 31,256 | ||
| Change in fair value of derivative liabilities | 29,501 | 1,006,099 | ||
| Total other income | 30,087 | 1,037,355 | ||
| Provision for income taxes | 0 | 0 | ||
| NET LOSS | (1,306,361) | (556,903) | (2,172,176) | (2,343,491) |
| OTHER COMPREHENSIVE INCOME (LOSS) | ||||
| Foreign currency translation adjustments | 16,344 | 4,888 | 2,474 | (12,937) |
| Total Other Comprehensive Income (Loss) | 16,344 | 4,888 | 2,474 | (12,937) |
| TOTAL COMPREHENSIVE LOSS | $ (1,290,017) | $ (552,015) | $ (2,169,702) | $ (2,356,428) |
| Basic Loss per Common Share (in dollars per share) | $ (0.39) | $ (0.32) | $ (1.00) | $ (1.84) |
| Diluted Loss per Common Share (in dollars per share) | $ (0.40) | $ (0.32) | $ (1.46) | $ (1.84) |
| Basic Weighted Average Common Shares Outstanding (in shares) | 3,361,601 | 1,754,494 | 2,172,465 | 1,277,527 |
| Diluted Weighted Average Common Shares Outstanding (in shares) | 3,379,000 | 1,754,494 | 2,172,465 | 1,277,527 |
| X | ||||||||||
- Definition Represents the change in fair value for the period of warrant derivative liability. No definition available.
|
| X | ||||||||||
- Definition Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners. Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
|
| X | ||||||||||
- Definition The amount of expense recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non-production related depreciation. Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
|
| X | ||||||||||
- Definition The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period. Reference 1: http://www.xbrl.org/2003/role/disclosureRef
|
| X | ||||||||||
- Definition The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period. Reference 1: http://www.xbrl.org/2003/role/exampleRef
|
| X | ||||||||||
- Definition The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line. Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
|
| X | ||||||||||
- Definition Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations. Reference 1: http://www.xbrl.org/2003/role/disclosureRef
|
| X | ||||||||||
- Definition The portion of profit or loss for the period, net of income taxes, which is attributable to the parent. Reference 1: http://www.xbrl.org/2003/role/disclosureRef
|
| X | ||||||||||
- Definition Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense. No definition available.
|
| X | ||||||||||
- References No definition available.
|
| X | ||||||||||
- Definition The net result for the period of deducting operating expenses from operating revenues. No definition available.
|
| X | ||||||||||
- Definition Amount after tax and reclassification adjustments of gain (loss) on foreign currency translation adjustments, foreign currency transactions designated and effective as economic hedges of a net investment in a foreign entity and intra-entity foreign currency transactions that are of a long-term-investment nature. Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
|
| X | ||||||||||
- References No definition available.
|
| X | ||||||||||
- Definition Amount after tax of other comprehensive income (loss) attributable to parent entity. Reference 1: http://www.xbrl.org/2003/role/disclosureRef
|
| X | ||||||||||
- References No definition available.
|
| X | ||||||||||
- Definition Amount of income related to nonoperating activities, classified as other. Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
|
| X | ||||||||||
- Definition Amount of income (expense) related to nonoperating activities, classified as other. Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
|
| X | ||||||||||
- Definition A fee charged for services from professionals such as doctors, lawyers and accountants. The term is often expanded to include other professions, for example, pharmacists charging to maintain a medicinal profile of a client or customer. Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
|
| X | ||||||||||
- Definition The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use. Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
|
| X | ||||||||||
- Definition The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period. Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
|
| X | ||||||||||
- Definition Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period. Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
|